Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015732
Filing Date
2024-11-14
Accepted
2024-11-14 16:30:34
Documents
63
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rsls-20240930x10q.htm   iXBRL 10-Q 1712370
2 EX-31.1 rsls-20240930xex31d1.htm EX-31.1 11735
3 EX-31.2 rsls-20240930xex31d2.htm EX-31.2 12109
4 EX-32.1 rsls-20240930xex32d1.htm EX-32.1 9408
5 EX-32.2 rsls-20240930xex32d2.htm EX-32.2 9332
  Complete submission text file 0001558370-24-015732.txt   6220126

Data Files

Seq Description Document Type Size
6 EX-101.SCH rsls-20240930.xsd EX-101.SCH 38712
7 EX-101.CAL rsls-20240930_cal.xml EX-101.CAL 53149
8 EX-101.DEF rsls-20240930_def.xml EX-101.DEF 202868
9 EX-101.LAB rsls-20240930_lab.xml EX-101.LAB 355409
10 EX-101.PRE rsls-20240930_pre.xml EX-101.PRE 294903
66 EXTRACTED XBRL INSTANCE DOCUMENT rsls-20240930x10q_htm.xml XML 891878
Mailing Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673
Business Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673 949-429-6680
ReShape Lifesciences Inc. (Filer) CIK: 0001427570 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37897 | Film No.: 241463126
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)